PharmaEssentia USA Corporation has announced FDA approval and US launch of the BESREMi Pen for adults with polycythemia vera. The new device offers a more convenient self-administration option than the currently available pre-filled syringe and is expected to become commercially available in the coming weeks. BESREMi (ropeginterferon alfa-2b-njft) is already approved in over 40 countries for treating polycythemia vera, a cancer originating in bone marrow that causes chronic increases in blood cells. The company aims to support treatment consistency by simplifying self-administration. PharmaEssentia Corporation, headquartered in Taiwan, is a global biopharmaceutical company with operations in the US, Japan, China and Korea. The company plans to seek label expansion for the drug to include essential thrombocythaemia.

PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen(TM)(ropeginterferon alfa-2b-njft) for Polycythemia Vera. New pre-filled pen device enhances patient experience by simplifying self-administration BURLINGTON, Mass.-(BUSINESS WIRE)-PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the U.S. Food and Drug Administration (FDA) approval and launch of the BESREMi Pen(TM)(ropeginterferon alfa-2b-njft) device for adult patients with polycythemia vera (PV). The device offers a more convenient self-administration option than the currently available pre-filled syringe. The BESREMi Pen(TM) is expected to become commercially available in the U.S. in the coming weeks. "The U.S. approval of the BESREMi Pen(TM) is a significant milestone both for our company, as well as the patients we serve," said Samuel Lin, Head of Global Operations, PharmaEssentia. "With this new device, we're empowering more people living with PV to manage their condition with greater ease and confidence. It reflects our continued commitment to delivering not only innovative therapeutics, but also smarter, more intuitive ways to support long-term care." "I'm very excited to see the FDA approval of the BESREMi Pen(TM) as a new option for patients," said Dr. John Mascarenhas, Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at Mount Sinai in New York City. "Treatment consistency is critical for managing PV, and this device has the potential to make a meaningful positive impact on patients' lives by simplifying self-administration and supporting better adherence." About PharmaEssentia PharmaEssentia USA Corporation, located in Burlington, Massachusetts, is a subsidiary of PharmaEssentia Corporation (TWSE: 6446). PharmaEssentia Corporation, headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. About Polycythemia Vera (PV) Polycythemia vera (PV) is a cancer originating from a disease-initiating stem cell in the bone marrow resulting in a chronic increase of red blood cells, white blood cells and platelets. PV may result in cardiovascular complications such as thrombosis and embolism, and often transforms to secondary myelofibrosis or leukemia. While the molecular mechanism underlying PV is still subject of intense research, current results point to a set of acquired mutations, the most important being a mutant form of JAK2. About BESREMi(R)(ropeginterferon alfa-2b-njft) Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi(R) for the treatment of adults with polycythemia vera (PV). The Company plans to seek a ropeginterferon alfa-2b-njft label expansion to include ET and has submitted a sBLA with the U.S. FDA. BESREMi(R) holds orphan drug designation in the United States for the treatment of polycythemia vera (PV) in adults. It has received regulatory approval in over 40 countries, including from the European Medicines Agency (2019), the U.S. Food and Drug Administration (2021), and the Pharmaceuticals and Medical Devices Agency in Japan (2023). The product was developed by PharmaEssentia. PharmaEssentia retains full global intellectual property rights across all indications. INDICATION BESREMi(R) is indicated for the treatment of adults with polycythemia vera. IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS DISORDERS Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping therapy. CONTRAINDICATIONS Existence of or history of severe depression, suicidal ideation, or suicide attempt Hypersensitivity to interferons or any inactive ingredients Moderate or severe hepatic impairment History or presence of active serious or untreated autoimmune disease History of transplantation and receiving immunosuppressant agents WARNINGS AND PRECAUTIONS Patients exhibiting the following events should be closely monitored and may require dose reduction or discontinuation of therapy: * Depression and Suicide: Monitor closely for symptoms and need for treatment. * Endocrine Toxicity: Discontinue if endocrine disorders occur that cannot be medically managed. * Cardiovascular Toxicity: Avoid use in patients with severe, acute or unstable cardiovascular disease. Monitor patients with history of cardiovascular disorders more frequently. * Decreased Peripheral Blood Counts: Perform blood counts at baseline, every 2 weeks during titration, and at least every 3-6 months during maintenance treatment. * Hypersensitivity Reactions: Stop treatment and immediately manage reaction. * Pancreatitis: Consider discontinuation if confirmed pancreatitis * Colitis: Discontinue if signs or symptoms of colitis * Pulmonary Toxicity: Discontinue if pulmonary infiltrates or pulmonary function impairment * Ophthalmologic Toxicity: Advise patients to have eye examinations before and during treatment. Evaluate eye symptoms promptly and discontinue if new or worsening eye disorders. * Hyperlipidemia: Monitor serum triglycerides before BESREMi(R) treatment and intermittently during therapy and manage when elevated. * Hepatotoxicity: Monitor liver enzymes and hepatic function at baseline and during treatment. Reduce dose or discontinue depending on severity. * Renal Toxicity: Monitor serum creatinine at baseline and during therapy. Discontinue if severe renal impairment develops. * Dental and Periodontal Toxicity: Advise patients on good oral hygiene and to have regular dental examinations. * Dermatologic Toxicity: Consider discontinuing if clinically significant dermatologic toxicity. * Driving and Operating Machinery: Advise patients to avoid driving or using machinery if they experience dizziness, somnolence, or hallucination. Contacts. Media Muriel Huang Director, Investor Relations and Corporate Communication [email protected] More News From PharmaEssentia USA Corporation BURLINGTON, Mass.-( BUSINESS WIRE )-PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan, today announced the acquisition of FORUS Therapeutics Inc. ("FORUS"), a Canadian specialty pharmaceutical company, in a transaction valued at US$36.5 million. The acquisition represents an important component of PharmaEssentia's North American commercial strategy and marks a significant milestone in the company's global expansion. PharmaEssentia entered into a... BURLINGTON, Mass.-( BUSINESS WIRE )-PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the Taiwan's Ministry of Health and Welfare (MOHW) has approved ropeginterferon alfa-2b-njft (BESREMi(R) for the treatment of adult patients with essential thrombocythemia (ET). BESREMi(R) is... BURLINGTON, Mass.-( BUSINESS WIRE )-PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan, announced that Eric Vogel has joined the company as U.S. Head of Commercialization. A seasoned commercial leader with more than 20 years of experience in oncology and hematology, Vogel will support Samuel Lin, Head of Global Operations, in driving the commercial growth of BESREMi(R)(ropeginterferon alfa-2b-njft) for approved uses across global markets. Vogel jo... PharmaEssentia USA Corporation. Headquarters: Taipei, Taiwan CEO: Ko-Chung Lin Employees: 600 Organization: PUB Release Versions Media Muriel Huang Director, Investor Relations and Corporate Communication [email protected]

PharmaEssentia acquires FORUS Therapeutics to expand Canadian commercial operations. June 11, 2026 PharmaEssentia Corporation has acquired Canadian specialty pharmaceutical company FORUS Therapeutics in a transaction valued at $36.5 million, advancing the Taiwan-based biopharmaceutical company's strategy to expand its commercial presence across North America and strengthen its position in hematology and oncology markets. The acquisition gives PharmaEssentia full ownership of FORUS and brings the company's Canadian regulatory, medical affairs, market access and commercial operations in-house. The move follows a commercial licensing agreement signed in 2024 under which FORUS was responsible for the Canadian commercialization of BESREMi(R)(ropeginterferon alfa-2b), PharmaEssentia's treatment for polycythemia vera (PV). The deal is expected to enhance PharmaEssentia's ability to support the anticipated Canadian launch of BESREMi and establish a broader commercial infrastructure for future products in the region. FORUS submitted a New Drug Submission to Health Canada for ropeginterferon alfa-2b in July 2025, with regulatory approval expected in the third quarter of 2026. The company is also preparing a submission seeking approval for the treatment of essential thrombocythemia (ET), which would further expand the product's addressable market. "This acquisition is the culmination of a strong and proven partnership with the FORUS team," said Dr. Ko-Chung Lin, founder and chief executive officer of PharmaEssentia. "By bringing their regulatory expertise, market relationships and medical and commercial capabilities fully in-house, we are best positioned to accelerate BESREMi's availability to patients with MPN across Canada and to build a durable North American platform for our growing portfolio." The transaction provides PharmaEssentia with an established commercial organization that has extensive experience in hematology and oncology product launches. FORUS executives and team members collectively bring more than 25 years of commercialization experience and have held leadership positions at pharmaceutical companies including Celgene, Roche and Pfizer. According to the company, the team has participated in more than 10 product launches that generated over C$2 billion in cumulative sales. FORUS Chief Executive Officer Kevin Leshuk, who spent more than a decade at Celgene building and leading its Canadian operations, will join PharmaEssentia as part of the acquisition. Leshuk said the transaction creates opportunities to expand the company's hematology and oncology presence while leveraging existing commercial infrastructure. "Joining PharmaEssentia marks an exciting new chapter and opportunity for the FORUS team," Leshuk said. "This acquisition now provides the local team the opportunity to build upon the existing experience with XPOVIO and leverage combined capabilities, infrastructure and expertise as we build a leading MPN and hematology-oncology franchise in Canada." In addition to supporting BESREMi, the acquisition could create strategic opportunities related to FORUS' existing partnership with Karyopharm Therapeutics and its oncology product XPOVIO. PharmaEssentia said the combined platform may allow it to explore additional market synergies and future growth opportunities within Canada's specialty pharmaceutical sector. The acquisition reflects a broader trend among emerging biopharmaceutical companies seeking greater control over commercialization activities in key international markets. By integrating commercial operations directly, companies can manage regulatory engagement, market access strategies and physician education efforts more closely while capturing a larger share of product revenues. PharmaEssentia has steadily expanded its global footprint in recent years as it commercializes BESREMi and advances a pipeline focused on hematology, oncology and immunology. Founded in 2003 and headquartered in Taipei, Taiwan, the company maintains operations in the United States, Japan, China and South Korea, supported by a biologics manufacturing facility in Taichung. BESREMi is approved by the U.S. Food and Drug Administration for the treatment of adults with polycythemia vera and currently holds regulatory approvals in more than 40 countries. PharmaEssentia is pursuing additional indications, including essential thrombocythemia, as it seeks to broaden the therapy's role in the treatment of myeloproliferative neoplasms and strengthen its presence in global hematology markets.